FDA’s CDRH Launches a Rare Disease Device Initiative

FDA's Center for Devices and Radiological Health has opened a Rare Disease Impact Initiative, a centralized effort to close what the agency describes as a persistent gap in medical devices for small patient populations. The program, live on FDA's site as of 11 September, pairs a new public device list with structured engagement channels for developers, patients, and caregivers — the device center's answer to a problem the drug side of the agency has been working on since 2022.

Why devices lag drugs on rare disease

The device side of FDA has had rare-disease tools for decades — the Humanitarian Device Exemption (HDE) pathway, aimed at devices for U.S. populations under 8,000 patients a year, dates to the 1990s. What CDRH lacked until now was a single door: a place where developers, clinicians, and patient advocacy groups could find which devices already exist for a given rare condition, and where CDRH itself would field questions about a pathway rather than leaving sponsors to work out precedent case by case. The initiative doesn’t change any submission requirement. It is infrastructure — a list, an inbox, and a workshop calendar — layered on top of routes that already exist.

What the device list actually shows

The Rare Disease Medical Device List is exactly that: devices already authorized for marketing in the U.S. that carry a rare-disease or rare-condition indication, gathered into one place for the first time as an official CDRH resource. FDA frames it as a tool for visibility and transparency into the current device landscape for rare diseases rather than a comprehensive registry. For a sponsor evaluating whether a predicate or comparable device already exists for a target population, that turns what used to be an ad hoc database search into a documented starting point.

The companion workshop, and the drug-side precedent

CDRH's initiative sits alongside a workshop calendar rather than a single announcement. Its next event, the third in FDA's RISE (Rare disease Innovation, Science, and Exploration) series, is scheduled for 29 September 2026 under the title “RISE to the Challenge: Statistical Considerations for Rare Disease Clinical Investigations.” Its subject — how to size and analyze a trial when the entire eligible population might be a few hundred people worldwide — sits squarely inside the problem the initiative is built to address. On the drug side, CDER has run a comparable Accelerating Rare Disease Cures (ARC) Program since 2022; CDRH's initiative reads as the device center building its own version of that infrastructure, several years behind but modeled on the same idea: centralize the resources so sponsors and patient groups stop rediscovering the same answers from scratch.

For a device sponsor already working a rare-disease submission, the practical change is a point of contact rather than a change in pathway: CDRH-Rare@fda.hhs.gov reaches the center directly, and a cleared device can now expect to be added to a public list that patients, clinicians, and other sponsors will consult.